Company attributes
Other attributes
Denali Therapeutics Inc. is a biotechnology company that focuses on the discovery and development of therapies for patients who are suffering from neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, ALS and more.
Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines.
Denali Therapeutics develops a wide portfolio of drug candidates that possess the potential to improve the lives of patients by addressing the causes and risk factors of neurodegenerative diseases.
Denali is pursuing a science-driven approach to translational medicine and clinical development. Its founding investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund (represented by Crestline Investors).
